Genscript Biotech Stock Analysis
| GNNSF Stock | USD 1.84 0.00 0.00% |
Genscript Biotech holds a debt-to-equity ratio of 0.564. Genscript Biotech's financial risk is the risk to Genscript Biotech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Genscript Biotech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Genscript Biotech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Genscript Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Genscript Biotech's stakeholders.
For many companies, including Genscript Biotech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Genscript Biotech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Genscript Biotech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Genscript Biotech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Genscript Biotech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Genscript Biotech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Genscript Biotech is said to be less leveraged. If creditors hold a majority of Genscript Biotech's assets, the Company is said to be highly leveraged.
Genscript Biotech is undervalued with Real Value of 1.92 and Hype Value of 1.84. The main objective of Genscript Biotech pink sheet analysis is to determine its intrinsic value, which is an estimate of what Genscript Biotech is worth, separate from its market price. There are two main types of Genscript Biotech's stock analysis: fundamental analysis and technical analysis.
The Genscript Biotech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Genscript Biotech's ongoing operational relationships across important fundamental and technical indicators.
Genscript |
Genscript Pink Sheet Analysis Notes
About 38.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 200.0. Genscript Biotech recorded a loss per share of 0.17. The entity last dividend was issued on the 5th of June 2017. Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.The quote for Genscript Biotech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Genscript Biotech call Brian Min at 86 25 5889 7288 or check out https://www.genscript.com.Genscript Biotech Investment Alerts
| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| Genscript Biotech has high historical volatility and very poor performance | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
Genscript Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.67 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genscript Biotech's market, we take the total number of its shares issued and multiply it by Genscript Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Genscript Profitablity
The company has Profit Margin (PM) of (0.66) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.Technical Drivers
As of the 7th of February, Genscript Biotech retains the Market Risk Adjusted Performance of (0.77), risk adjusted performance of (0.03), and Standard Deviation of 3.35. Genscript Biotech technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genscript Biotech variance and skewness to decide if Genscript Biotech is priced fairly, providing market reflects its last-minute price of 1.84 per share. Please also validate Genscript Biotech information ratio, which is currently at (0.07) to confirm the company can sustain itself at a future point.Genscript Biotech Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Genscript Biotech Predictive Daily Indicators
Genscript Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genscript Biotech pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Genscript Biotech Forecast Models
Genscript Biotech's time-series forecasting models are one of many Genscript Biotech's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genscript Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Genscript Biotech Debt to Cash Allocation
Many companies such as Genscript Biotech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Genscript Biotech has accumulated 121.07 M in total debt with debt to equity ratio (D/E) of 0.56, which is about average as compared to similar companies. Genscript Biotech has a current ratio of 2.86, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genscript Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Genscript Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genscript Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genscript to invest in growth at high rates of return. When we think about Genscript Biotech's use of debt, we should always consider it together with cash and equity.Genscript Biotech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Genscript Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Genscript Biotech, which in turn will lower the firm's financial flexibility.About Genscript Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Genscript Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Genscript shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Genscript Biotech. By using and applying Genscript Pink Sheet analysis, traders can create a robust methodology for identifying Genscript entry and exit points for their positions.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Genscript Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |